| Identification | Back Directory | [Name]
N-[(1R)-1-[3′-(Aminocarbonyl)[1,1′-biphenyl]-4-yl]-2-(1-pyrrolidinyl)ethyl]-6,7-dichloro-2,3-dihydro-N-methyl-3-oxo-4H-1,4-benzoxazine-4-acetamide | [CAS]
1003877-55-1 | [Synonyms]
GSK-1562590
N-[(1R)-1-[3′-(Aminocarbonyl)[1,1′-biphenyl]-4-yl]-2-(1-pyrrolidinyl)ethyl]-6,7-dichloro-2,3-dihydro-N-methyl-3-oxo-4H-1,4-benzoxazine-4-acetamide | [Molecular Formula]
C30H30Cl2N4O4 | [MOL File]
1003877-55-1.mol | [Molecular Weight]
581.49 |
| Chemical Properties | Back Directory | [Boiling point ]
841.6±65.0 °C(Predicted) | [density ]
1.347±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | [pka]
15.84±0.50(Predicted) |
| Hazard Information | Back Directory | [Uses]
GSK-1562590 is a uropeptide-II receptor antagonist with high affinity and selectivity. GSK-1562590 exhibits significant antagonistic activity in multiple bioassays and, in contrast, displays relatively sustained receptor binding times. GSK-1562590 can inhibit human urinary peptide-II-induced aortic contraction in rats in experiments, and its effect can last for at least 24 hours[1]. | [References]
[1] GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo DOI:10.1111/j.1476-5381.2010.00889.x |
|
|